- Home
- DFIN vs KROS Comparison
DFIN vs KROS Comparison
Compare DFIN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- KROS
- Stock Information
- Founded
- DFIN 1983
- KROS 2015
- Country
- DFIN United States
- KROS United States
- Employees
- DFIN N/A
- KROS N/A
- Industry
- DFIN Other Consumer Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- KROS Health Care
- Exchange
- DFIN Nasdaq
- KROS Nasdaq
- Market Cap
- DFIN 1.2B
- KROS 558.9M
- IPO Year
- DFIN N/A
- KROS 2020
- Fundamental
- Price
- DFIN $64.19
- KROS $14.17
- Analyst Decision
- DFIN Strong Buy
- KROS Buy
- Analyst Count
- DFIN 3
- KROS 13
- Target Price
- DFIN $68.67
- KROS $20.63
- AVG Volume (30 Days)
- DFIN 248.5K
- KROS 601.6K
- Earning Date
- DFIN 07-30-2025
- KROS 08-06-2025
- Dividend Yield
- DFIN N/A
- KROS N/A
- EPS Growth
- DFIN N/A
- KROS N/A
- EPS
- DFIN 3.01
- KROS 0.11
- Revenue
- DFIN $779,600,000.00
- KROS $214,713,000.00
- Revenue This Year
- DFIN $1.99
- KROS $5,006.76
- Revenue Next Year
- DFIN $4.64
- KROS N/A
- P/E Ratio
- DFIN $21.30
- KROS $127.57
- Revenue Growth
- DFIN N/A
- KROS 91657.70
- 52 Week Low
- DFIN $37.80
- KROS $9.12
- 52 Week High
- DFIN $71.01
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- DFIN 80.71
- KROS 59.31
- Support Level
- DFIN $61.12
- KROS $13.26
- Resistance Level
- DFIN $64.55
- KROS $13.77
- Average True Range (ATR)
- DFIN 1.06
- KROS 0.37
- MACD
- DFIN 0.11
- KROS 0.05
- Stochastic Oscillator
- DFIN 93.32
- KROS 92.54
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.